Acrux Limited (ASX:ACR)
Australia · Delayed Price · Currency is AUD 0.0110
+0.0010 (10.00%)
Oct 9, 2026, 4:10 PM AEST
Acrux Revenue
In the fiscal year ending June 30, 2026, Acrux had annual revenue of 6.58M AUD with 46.64% growth. Acrux had revenue of 4.84M in the half year ending June 30, 2026, with 36.17% growth. That makes Acrux the 40,206th largest company in the world by revenue and 777th in Australia.
Revenue
6.58M
Revenue Growth
+46.64%
P/S Ratio
0.99
Revenue / Employee
153.05K
Employees
43
Market Cap
6.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 6.58M | 2.09M | 46.64% |
| Jun 30, 2025 | 4.49M | -3.48M | -43.65% |
| Jun 30, 2024 | 7.96M | -465.00K | -5.52% |
| Jun 30, 2023 | 8.43M | 6.71M | 390.34% |
| Jun 30, 2022 | 1.72M | 382.00K | 28.57% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.71M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cynata Therapeutics | 1.71M |
| Bio-Gene Technology | 1.08M |
| Nexalis Therapeutics | 1.07M |
| Biotron | 525.87K |
| AdAlta | 404.25K |